JPWO2022125982A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022125982A5 JPWO2022125982A5 JP2023534899A JP2023534899A JPWO2022125982A5 JP WO2022125982 A5 JPWO2022125982 A5 JP WO2022125982A5 JP 2023534899 A JP2023534899 A JP 2023534899A JP 2023534899 A JP2023534899 A JP 2023534899A JP WO2022125982 A5 JPWO2022125982 A5 JP WO2022125982A5
- Authority
- JP
- Japan
- Prior art keywords
- invention described
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063124064P | 2020-12-11 | 2020-12-11 | |
US63/124,064 | 2020-12-11 | ||
US202063130106P | 2020-12-23 | 2020-12-23 | |
US63/130,106 | 2020-12-23 | ||
PCT/US2021/062946 WO2022125982A1 (en) | 2020-12-11 | 2021-12-10 | Compositions and methods for reducing mhc class ii in a cell |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2023552816A JP2023552816A (ja) | 2023-12-19 |
JPWO2022125982A5 true JPWO2022125982A5 (enrdf_load_stackoverflow) | 2024-12-19 |
Family
ID=80168106
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023534899A Pending JP2023552816A (ja) | 2020-12-11 | 2021-12-10 | 細胞内のmhcクラスiiを低減する組成物及び方法 |
Country Status (13)
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4544058A1 (en) * | 2022-06-23 | 2025-04-30 | Chroma Medicine, Inc. | Compositions and methods for epigenetic regulation of ciita expression |
US20240189355A1 (en) * | 2022-11-14 | 2024-06-13 | WUGEN, Inc. | Hypoimmunogenic cells having targeted modifications in mhc class-i genes and methods of use |
CN118922551A (zh) * | 2023-01-30 | 2024-11-08 | 南京北恒生物科技有限公司 | 用于CRISPR-Cas基因编辑系统的方法及组合物 |
TW202515992A (zh) | 2023-08-14 | 2025-04-16 | 美商英特利亞醫療公司 | 用於對轉形生長因子β受體2型(TGFβR2)進行基因修飾之組合物及方法 |
WO2025038642A1 (en) | 2023-08-14 | 2025-02-20 | Intellia Therapeutics, Inc. | Compositions and methods for genetically modifying cd70 |
WO2025038637A1 (en) | 2023-08-14 | 2025-02-20 | Intellia Therapeutics, Inc. | Compositions and methods for genetically modifying transforming growth factor beta receptor type 2 (tgfβr2) |
WO2025038646A1 (en) | 2023-08-14 | 2025-02-20 | Intellia Therapeutics, Inc. | Cd70 car-t compositions and methods for cell-based therapy |
WO2025049481A1 (en) * | 2023-08-28 | 2025-03-06 | Intellia Therapeutics, Inc. | Methods of editing an hla-a gene in vitro |
WO2025049432A1 (en) * | 2023-08-28 | 2025-03-06 | Intellia Therapeutics, Inc. | Methods for editing hla-a in cells pre-screened for the absence of one or both alleles of hla-h*01 |
WO2025128871A2 (en) | 2023-12-13 | 2025-06-19 | Renagade Therapeutics Management Inc. | Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5585481A (en) | 1987-09-21 | 1996-12-17 | Gen-Probe Incorporated | Linking reagents for nucleotide probes |
US5378825A (en) | 1990-07-27 | 1995-01-03 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogs |
EP1044987B1 (en) | 1991-12-24 | 2006-02-15 | Isis Pharmaceuticals, Inc. | Gapped 2'-modified oligonucleotides |
AU2522095A (en) | 1994-05-19 | 1995-12-18 | Dako A/S | Pna probes for detection of neisseria gonorrhoeae and chlamydia trachomatis |
CN103668470B (zh) | 2012-09-12 | 2015-07-29 | 上海斯丹赛生物技术有限公司 | 一种dna文库及构建转录激活子样效应因子核酸酶质粒的方法 |
US20140310830A1 (en) | 2012-12-12 | 2014-10-16 | Feng Zhang | CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes |
WO2014093655A2 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains |
WO2014099744A1 (en) | 2012-12-17 | 2014-06-26 | President And Fellows Of Harvard College | Rna-guided human genome engineering |
US9840699B2 (en) | 2013-12-12 | 2017-12-12 | President And Fellows Of Harvard College | Methods for nucleic acid editing |
US10342761B2 (en) | 2014-07-16 | 2019-07-09 | Novartis Ag | Method of encapsulating a nucleic acid in a lipid nanoparticle host |
ES2688035T3 (es) | 2014-08-29 | 2018-10-30 | Gemoab Monoclonals Gmbh | Receptor de antígeno universal que expresa células inmunes para direccionamiento de antígenos múltiples diversos, procedimiento para fabricación del mismo y utilización del mismo para tratamiento de cáncer, infecciones y enfermedades autoinmunes |
EP3265559B1 (en) | 2015-03-03 | 2021-01-06 | The General Hospital Corporation | Engineered crispr-cas9 nucleases with altered pam specificity |
EA201891338A1 (ru) * | 2015-12-04 | 2018-12-28 | Новартис Аг | Композиции и способы для иммуноонкологии |
US20190136231A1 (en) | 2016-03-30 | 2019-05-09 | Intellia Therapeutics, Inc. | Lipid nanoparticle formulations for crispr/cas components |
WO2018073393A2 (en) | 2016-10-19 | 2018-04-26 | Cellectis | Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy |
EA201991369A1 (ru) | 2016-12-08 | 2019-12-30 | Интеллиа Терапьютикс, Инк. | Модифицированные направляющие рнк |
AU2018266698A1 (en) | 2017-05-08 | 2019-11-28 | Precision Biosciences, Inc. | Nucleic acid molecules encoding an engineered antigen receptor and an inhibitory nucleic acid molecule and methods of use thereof |
CA3062506A1 (en) * | 2017-05-12 | 2019-05-23 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
SMT202400172T1 (it) | 2017-09-29 | 2024-07-09 | Intellia Therapeutics Inc | Formulazioni |
WO2019118516A1 (en) * | 2017-12-11 | 2019-06-20 | Editas Medicine, Inc. | Cpf1-related methods and compositions for gene editing |
WO2019147805A2 (en) | 2018-01-26 | 2019-08-01 | The Board Of Trustees Of The Leland Stanford Junior University | Regulatory t cells targeted with chimeric antigen receptors |
EP3775229A4 (en) | 2018-03-27 | 2021-12-15 | The Trustees Of The University Of Pennsylvania | MODIFIED IMMUNE CELLS WITH IMPROVED FUNCTION AND SCREENING METHODS TO IDENTIFY THEM |
JP2021526804A (ja) | 2018-06-08 | 2021-10-11 | インテリア セラピューティクス,インコーポレイテッド | 遺伝子編集のための修飾されたガイドrna |
WO2019237035A1 (en) * | 2018-06-08 | 2019-12-12 | Intellia Therapeutics, Inc. | Compositions and methods for immunooncology |
EP3581200A1 (en) | 2018-06-13 | 2019-12-18 | GEMoaB Monoclonals GmbH | Reversed universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders |
CN113166743A (zh) | 2018-10-15 | 2021-07-23 | 马萨诸塞大学 | Nme2cas9-脱氨酶融合蛋白的可编程dna碱基编辑 |
EP3867379A1 (en) | 2018-10-16 | 2021-08-25 | Intellia Therapeutics, Inc. | Compositions and methods for immunotherapy |
WO2020092057A1 (en) | 2018-10-30 | 2020-05-07 | Yale University | Compositions and methods for rapid and modular generation of chimeric antigen receptor t cells |
EP3924375A4 (en) * | 2019-02-15 | 2023-03-22 | President and Fellows of Harvard College | Universal donor stem cells and related methods |
-
2021
- 2021-12-10 MX MX2023006878A patent/MX2023006878A/es unknown
- 2021-12-10 CR CR20230303A patent/CR20230303A/es unknown
- 2021-12-10 EP EP21852082.3A patent/EP4259783A1/en active Pending
- 2021-12-10 AU AU2021396403A patent/AU2021396403A1/en active Pending
- 2021-12-10 CA CA3204997A patent/CA3204997A1/en active Pending
- 2021-12-10 WO PCT/US2021/062946 patent/WO2022125982A1/en not_active Application Discontinuation
- 2021-12-10 IL IL303505A patent/IL303505A/en unknown
- 2021-12-10 JP JP2023534899A patent/JP2023552816A/ja active Pending
- 2021-12-10 TW TW110146323A patent/TW202235617A/zh unknown
- 2021-12-10 KR KR1020237022783A patent/KR20230130635A/ko not_active Withdrawn
-
2023
- 2023-06-09 US US18/332,390 patent/US20240016934A1/en active Pending
- 2023-06-09 CL CL2023001688A patent/CL2023001688A1/es unknown
- 2023-07-05 CO CONC2023/0008922A patent/CO2023008922A2/es unknown
- 2023-10-17 CL CL2023003085A patent/CL2023003085A1/es unknown